Management of diabetic foot infections in an era of increasing microbial resistance

Current Infectious Disease Reports

Volumn 11, Issue 5, 2009, Pages 375-382

  Nelson, Sandra Bliss ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; ANTIINFECTIVE AGENT; DAPTOMYCIN; ERTAPENEM; LINEZOLID; OFLOXACIN; PENICILLIN G; PEXIGANAN ACETATE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; BONE BIOPSY; CLINICAL TRIAL; DIABETIC FOOT; DIABETIC FOOT INFECTION; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DRUG TOLERABILITY; HUMAN; HYDROTHERAPY; INFECTIOUS COMPLICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PROBE TO BONE TEST; REVIEW; SKIN INFECTION; THROMBOCYTOPENIA;

EID: 69249098967     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0053-z     Document Type: Review

References (46)

1. Singh N, Armstrong DG, Lipsky BA: Preventing foot ulcers in patients with diabetes. JAMA 2005, 293:217-228.
2. Prompers L, Huijberts M, Apelqvist J, et al.: High prevalence of ischaemia, infection, and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007, 50:18-25.
3. Lavery LA, Armstrong DG, Wunderlich RP, et al.: Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006, 29:1288-1293.
4. National Institute of Diabetes and Digestive and Kidney Diseases: National Diabetes Statistics 2007. Available at http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#complications. Accessed May 2009.
5. Lipsky BA, Berendt AR, Deery HG, et al.: Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004, 39:885-910.
6. Citron DM, Goldstein EJC, Merriam CV, et al.: Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007, 45:2819-2828.
7. Dowd SE, Wolcott RD, Sun Y, et al.: Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One 2008, 3:e3326.
8. Hartemann-Heurtier A, Robert J, Jacqueminet S, et al.: Diabetic foot ulcer and multidrug-resistant organisms: Risk factors and impact. Diabet Med 2004, 21:710-715.
9. Richard JL, Sotto A, Jourdan N, et al.: Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metab 2008, 34:363-369.
10. Kandemir O, Akbay E, Sahin E, et al.: Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect 2007, 54:439-445.
11. Tentolouris N, Jude EB, Smirnof I et al.: Methicillin-resistant Staphylococcus aureus: An increasing problem in a diabetic foot clinic. Diabet Med 1999, 16:767-771.
12. Wagner A, Reike H, Angelkort B: Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections. Dtsch Med Wochenschr 2001, 126:1353-1356.
13. Dang CN, Prasad YDM, Boulton AJM, Jude EB: Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: A worsening problem. Diabet Med 2003, 20:159-161.
14. Tentolouris N, Petrikkos G, Vallianou N, et al.: Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect 2006, 12:178-196.
15. Stanaway S, Johnson D, Moulik P, Gill G: Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res Clin Pract 2007, 75:47-50.
16. Lipsky BA: New developments in diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev 2008, 24:S66-S71.
17. Chang S, Sievert DM, Hageman JC et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. New Engl J Med 2003, 348:1342-1347.
18. Shankar EM, Mohan V, Premalatha G, et al.: Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med 2005, 16:567-570.
19. Varaiya AY, Dogra JD, Kulkarni MH, Bhalekar PN: Extended-spectrum beta-lactamase-producing Escherichia coli and Klebseilla pneumoniae in diabetic foot infections. Indian J Pathol Microbiol 2008, 51:370-372.
20. Game F, Jeffcoate W: MRSA and osteomyelitis of the foot in diabetes. Diabet Med 2004, 21:16-19.
21. Vardakas KZ, Horianopoulou M, Falagas ME: Factors associated with treatment failure in patients with diabetic foot infections: An analysis of data from randomized controlled trials. Diabetes Res Clin Pract 2008, 80:344-351.
22. Lipsky BA: Medical treatment of diabetic foot infections. Clin Infect Dis 2004, 39:S104-S114.
23. Lavery LA, Armstrong DG, Peters EJG, Lipsky BA: Probeto-bone test for diagnosing diabetic foot osteomyelitis: Reliable or relic. Diabetes Care 2007, 30:270-274.
24. Butalia S, Palda VA, Sargeant RJ, et al.: Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA 2008, 299:806-813.
25. Dinh MT, Abad CL, Safdar N: Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: Meta-analysis. Clin Infect Dis 2008, 47:519-527.
26. Slater RA, Lazarovitch T, Boldur I, et al.: Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med 2004, 21:705-709.
27. Pellizzer G, Strazzabosco M, Presi S, et al.: Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med 2001, 18:822-827.
28. Senneville E, Lombart A, Beltrand E, et al.: Outcome of diabetic foot osteomyelitis treated nonsurgically. Diabetes Care 2008, 31:637-642.
29. Senneville E, Morant H, Descamps D, et al.: Needle puncture and transcutaneous bone biopsy cultures are inconsistent in patients with diabetes and suspected osteomyelitis of the foot. Clin Infect Dis 2009, 48:888-893.
30. Senneville E, Melliez H, Beltrand E, et al.: Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis 2006, 42:57-62.
31. Oberdorfer K, Swoboda S, Hamann A, et al.: Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother 2004, 54:836-839.
32. Legat FJ, Krause R, Zenahlik P, et al.: Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob Agents Chemother 2005, 49:4368-4371.
33. Stein GE, Schooley S, Peloquin CA, et al.: Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007, 60:819-823.
34. Lipsky BA, Stoutenburgh U: Daptomycin for treating infected diabetic foot ulcers: Evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin structure infections. J Antimicrob Chemother 2005, 55:240-245.
35. Lipsky BA: Empirical therapy for diabetic Aoot infections: are there clinical clues to guide antibiotic selection. Clin Microbiol Infect 2007, 13:351-353.
36. Berendt AR, Peters EJG,ABakker K, et al.: Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 2008, 24:S145-S161.
37. Lipsky BA, Itani K, Norden C; Linezolid Diabetic Foot Infections Study Group: Treating foot infections in diabetAc patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/ amoxicillin-clavulanate. Clin Infect Dis 2004, 38:17-24.
38. Arbeit RD, Maki D, Tally FP, et al.: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681.
39. Lipsky BA, Armstrong DG, Citron DM, et al.: Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, doubleblinded, multicentre trial. Lancet 2005, 366:1695-1703.
40. Stengel D, Gorzer E, Schintler M, et al.: Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin. J Chemother 2005, 17:527-535.
41. Tascini C, Menichetti F, Gemignani G, et al.: Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis. Int J Low Extrem Wounds 2006, 5:213-216.
42. Tascini C, Gemignani G, Palumbo F, et al.: Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 2006, 18:648-651.
43. Goldstein EJC, Citron DM, Warren YA, et al.: In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006, 50:2875-2879.
44. Goldstein EJC, Citron DM, Merriam CV, et al.: In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006, 50:3959-3962.
45. Jeffcoate WJ, Lipsky BA: Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis 2004, 39:S115-22.
46. Lipsky BA, Holroyd KJ, Zasloff M: Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: A randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 2008, 47:1537-1545.